Trial: 202103077

Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy

Phase

I/II

Principal Investigator

Johanns, Tanner

Disease Site

Melanoma, Skin

Learn more about this study at: clinicaltrials.gov